Cargando…

Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer: A systematic review and meta-analysis

PURPOSE: The clinical benefits provided by using anthracycline-contained regimens in patients with early breast cancer (EBC) remain uncertain. This meta-analysis used data from all relevant trials to compare treatment outcomes for patients with EBC receiving adjuvant chemotherapy with non–anthracycl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Wu, Li, Zhian, Wang, Caiyun, Dai, Jiangfeng, Ruan, GuoDong, Tu, Chuanjian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211907/ https://www.ncbi.nlm.nih.gov/pubmed/30335021 http://dx.doi.org/10.1097/MD.0000000000012908

Ejemplares similares

The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis
por: Ding, Wu, et al.
Publicado: (2018)

Cancer Therapy-Related Cardiac Dysfunction of Nonanthracycline Chemotherapeutics: What Is the Evidence?
por: Kamphuis, Janine A.M., et al.
Publicado: (2019)

Dynamic changes in marital status and survival in women with breast cancer: a population-based study
por: Ding, Wu, et al.
Publicado: (2021)

Metastatic site discriminates survival benefit of primary tumor surgery for differentiated thyroid cancer with distant metastases: A real-world observational study
por: Ding, Wu, et al.
Publicado: (2020)

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer
por: Huang, Liang, et al.
Publicado: (2015)

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
por: Chen, Wanjing, et al.
Publicado: (2021)

Chromosome instability and benefit from adjuvant anthracyclines in breast cancer
por: Munro, A F, et al.
Publicado: (2012)

Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer
por: Vaid, Ashok K., et al.
Publicado: (2020)

First Efficacy Results of Capecitabine with Anthracycline- and Taxane-Based Adjuvant Therapy in High-Risk Early Breast Cancer: A Meta-Analysis
por: Jiang, Yiwei, et al.
Publicado: (2012)

Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence
por: de Pinho, Inês Soares, et al.
Publicado: (2023)

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018)

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines
por: Berruti, A, et al.
Publicado: (2005)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

Anthracyclines in the treatment of patients with early breast cancer
por: Guarneri, V., et al.
Publicado: (2022)

Magnetic resonance imaging in screening women at high risk of breast cancer: A meta-analysis
por: Ding, Wu, et al.
Publicado: (2023)

Grading Evaluation of Cardiotoxicity in Patients with Breast Cancer Treated with Adjuvant Paclitaxel Anthracycline/Cyclophosphamide Chemotherapy: A Meta-Analysis
por: Hu, Weibao, et al.
Publicado: (2022)

Anthracyclines in the treatment of early breast cancer friend or foe?
por: Vuger, Ana Tecic, et al.
Publicado: (2022)

Retracted: Grading Evaluation of Cardiotoxicity in Patients with Breast Cancer Treated with Adjuvant Paclitaxel Anthracycline/Cyclophosphamide Chemotherapy: A Meta-Analysis
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis
por: Yu, Ke-Da, et al.
Publicado: (2013)

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients
por: Del Mastro, L, et al.
Publicado: (2005)

Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel
por: Berliere, Martine, et al.
Publicado: (2008)

Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel
por: Fountzilas, George, et al.
Publicado: (2012)

Incidence of Chemotherapy-Induced Amenorrhea After Adjuvant Chemotherapy With Taxane and Anthracyclines in Young Patients With Breast Cancer
por: Pourali, Leila, et al.
Publicado: (2013)

BCL-2, topoisomerase IIα, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy
por: Biesaga, Beata, et al.
Publicado: (2014)

Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy
por: Timotheadou, Eleni, et al.
Publicado: (2017)

The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients
por: Jensen, Maj-Britt, et al.
Publicado: (2020)

Tumor Glucose and Fatty Acid Metabolism in the Context of Anthracycline and Taxane-Based (Neo)Adjuvant Chemotherapy in Breast Carcinomas
por: Tőkés, Anna Mária, et al.
Publicado: (2022)

Microvessel Density and Status of p53 Protein as Potential Prognostic Factors for Adjuvant Anthracycline Chemotherapy in Retrospective Analysis of Early Breast Cancer Patients Group
por: Biesaga, Beata, et al.
Publicado: (2012)

Clinical significance of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy
por: LIU, WENJUAN, et al.
Publicado: (2015)

Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution
por: Ismaili, Nabil, et al.
Publicado: (2010)

Hepatitis B Reactivation During Adjuvant Anthracycline-Based Chemotherapy in Patients with Breast Cancer: A Single Institution's Experience
por: Kim, Min Kyoung, et al.
Publicado: (2007)

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer
por: Mori, Hitomi, et al.
Publicado: (2016)

Concurrent administration of trastuzumab and anthracyclines as adjuvant regimen for HER2-positive breast cancer: a randomised controlled trial
por: Shen, Songjie, et al.
Publicado: (2017)

PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients
por: Absmaier, Magdalena, et al.
Publicado: (2018)

Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial
por: Tan, Qiu-Wen, et al.
Publicado: (2017)

Risk Factors for Anthracycline-Induced Cardiotoxicity
por: Qiu, Shuo, et al.
Publicado: (2021)

The Quest for an Early Marker of Anthracycline-Induced Cardiotoxicity
por: Ibanez, Borja, et al.
Publicado: (2022)

6 versus 12 months of adjuvant trastuzumab in HER2+ early breast cancer: A systematic review and meta-analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2021)

PARPBP is a prognostic marker and confers anthracycline resistance to breast cancer
por: Chen, Bo, et al.
Publicado: (2020)

Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines
por: Mazzuca, Federica, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3ebjne8en9om9f7j0ee5gouect